NEONC TECHNOLOGIES HOLDINGS, INC.

NEONC TECHNOLOGIES HOLDINGS, INC. announced a change to its Board of Directors. Dr. Ming-Fu (Alan) Chiang resigned from his position as a Class II director and from the Scientific Advisory Board, effective June 27, 2026. Subsequently, on July 1, 2026, the Board elected Nasim Shomali as a new Class II director. Ms. Shomali, a former Strategy Executive at Accenture, is the niece of the Company's President, CEO, and Executive Chairman, Amir Heshmatpour.

NeOnc Technologies Holdings has secured its second Investigational New Drug (IND) authorization from the United Arab Emirates for NEO100, its lead intranasal therapy candidate for recurrent high-grade gliomas. This approval, which spans adult Phase 1-2 studies and a pediatric development pathway, follows an earlier UAE IND for its NEO212 program, significantly expanding its international regulatory footprint. The company anticipates reporting topline results from its fully enrolled NEO100-01 Phase 2a trial by the end of July. Additionally, insider purchases by the CEO and institutional interest highlight growing confidence in the company's prospects.

NEONC TECHNOLOGIES HOLDINGS, INC. announced its Annual Meeting of Stockholders to be held on August 14, 2026. Key proposals include the election of two Class I directors and an amendment to the 2023 Equity Incentive Plan. The proposed amendment seeks to increase the number of shares available for grant by 1,000,000 and incorporate annual increases equal to 20% of outstanding shares from 2027 to 2033. Shareholders will also vote on the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year 2026.

NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, its lead candidate. This authorization covers adult Phase 1 through Phase 2 studies and pediatric studies for progressive or recurrent Grade III or IV gliomas, expanding the company's clinical development in the UAE. NEO100 already holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations in the US, and the company anticipates reporting top-line Phase 2a data by the end of July 2026, which could support further regulatory opportunities.

NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, its orally administered drug for aggressive brain tumors. This clearance follows the successful completion of Phase 1, which established 610 mg as the recommended Phase 2 dose and showed encouraging early signs of clinical activity. The approval marks a significant international milestone, enabling Phase 2 evaluation in the UAE while the company continues discussions with the U.S. FDA for a potential registrational pathway.

NeOnc Technologies Holdings received Investigational New Drug (IND) authorization from the Department of Health – Abu Dhabi for NEO212, its oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors. This marks the first international regulatory clearance for NEO212, establishing a Phase 2 dose of 610 mg and opening a clinical development pathway outside the U.S. Additionally, the company's NEO100 program, targeting IDH1-mutant high-grade glioma, has achieved full enrollment in its Phase 2a study, with interim and top-line data anticipated later in 2026. The CEO has also invested over $500,000 in recent open-market stock purchases, bringing total insider purchases to nearly $1 million over the past year.

NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement to issue and sell up to $5 million of Series A Convertible Preferred Stock to accredited investors. The stock is priced at $833.34 per share. The issuance is exempt from registration under Section 4(a)(2) of the Securities Act. The company also amended its Certificate of Incorporation to authorize the Series A Preferred Stock, which has specific liquidation preferences and redemption/conversion terms. The company must file a registration statement for the resale of common stock issuable upon conversion.

The press release highlights the transformative role of artificial intelligence in healthcare, particularly in developing and delivering advanced therapeutics for brain and central nervous system conditions. It emphasizes the challenge of the blood-brain barrier in treating aggressive cancers like glioblastoma, which represents a significant unmet medical need. NeOnc Technologies Holdings is positioned as a key player in this evolving landscape, developing innovative therapies and delivery technologies. The article also notes the industry shift towards scalable "platform biotech models" and the early stages of AI-healthcare convergence.

NeOnc Technologies, a clinical-stage biotechnology company, is attracting significant attention from Wall Street analysts, institutional investors, and company insiders. Several firms, including Maxim Group and BTIG Research, initiated favorable coverage with advantageous ratings. CEO Amir Heshmatpour has consistently purchased shares, with recent acquisitions exceeding $500,000 and cumulative insider buying approaching $1 million over the past year. Institutional ownership is also expanding, with firms like Bank of America increasing positions, ahead of anticipated interim data for its lead brain cancer candidate, NEO100.

NeOnc Technologies Holdings, Inc. reported a net loss of $8.8 million, or $(0.38) per diluted share, for Q1 2026, a significant improvement from Q1 2025. The company also provided a business update, announcing the successful completion of the Phase 1 dose-escalation for NEO212, setting the recommended Phase 2 dose at 610 mg, and observing early signs of clinical activity. For NEO100, the Phase 2a study in recurrent IDH1-mutant high-grade glioma is fully enrolled with interim data expected in August 2026. Operationally, NeOnc strengthened its balance sheet with a $10 million PIPE financing and appointed David Choi as Chief Accounting Officer.